Wall Street brokerages expect that Gamida Cell Ltd (NASDAQ:GMDA) will report earnings per share of ($0.55) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Gamida Cell’s earnings. The firm is scheduled to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Gamida Cell will report full year earnings of ($1.95) per share for the current year. For the next year, analysts expect that the business will report earnings of ($1.50) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Gamida Cell.

Gamida Cell (NASDAQ:GMDA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.25).

Several analysts recently weighed in on the stock. Zacks Investment Research raised shares of Gamida Cell from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Friday, March 1st. ValuEngine cut shares of Gamida Cell from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Oppenheimer set a $20.00 target price on shares of Gamida Cell and gave the company a “buy” rating in a report on Tuesday, February 26th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $18.67.

NASDAQ:GMDA remained flat at $$7.20 during mid-day trading on Wednesday. 2,752 shares of the company traded hands, compared to its average volume of 17,114. The firm has a market capitalization of $174.40 million and a PE ratio of -0.68. Gamida Cell has a 52-week low of $6.65 and a 52-week high of $15.41. The company has a current ratio of 6.52, a quick ratio of 6.52 and a debt-to-equity ratio of 0.36.

A number of institutional investors have recently made changes to their positions in GMDA. Edmond DE Rothschild Holding S.A. purchased a new stake in Gamida Cell in the 1st quarter valued at about $53,000. Norges Bank purchased a new stake in Gamida Cell in the 4th quarter valued at about $88,000. FMR LLC purchased a new stake in Gamida Cell in the 4th quarter valued at about $1,243,000. Millennium Management LLC purchased a new stake in Gamida Cell in the 4th quarter valued at about $210,000. Finally, Delek Group Ltd. purchased a new stake in Gamida Cell in the 4th quarter valued at about $298,000. Institutional investors own 1.76% of the company’s stock.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

See Also: Risk Tolerance

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.